Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael S. Rogers, Ph.D.

Title
Institution
Department
Address
Phone
Fax

Mentoring
Available: 01/03/23, Expires: 01/31/24

Endometriosis is an inflammatory disease characterized by the presence of endometrium-like lesions, progressive abdominal or pelvic pain, and/or infertility. It affects ~10% of women of childbearing age and ~30% of patients are not effectively treated by existing options; new therapeutics are desperately needed. We have discovered that protectin DX (PDX) rapidly abolishes endometriosis-associated pain and shrinks lesions in a mouse model. Unfortunately, poor stability and pharmacokinetic properties render PDX a poor drug lead. To leverage the anti-endometriosis activity of PDX, its receptor must be identified. Similar molecules activate G-protein coupled receptors (GPCRs), thus we hypothesize that PDX acts through a GPCR. We aim to identify it and the cell type(s) expressing the PDX receptor. To that end, we will measure arrestin activation in a comprehensive library of human non-olfactory GPCRs. We will then identify the G-protein(s) that couple to this GPCR in the context of PDX signaling. To confirm that this is the relevant receptor, we will measure the effect of ablating this GPCR on the PDX-mediated increase in efferocytosis and up regulation of M2 markers in RAW264.7 cells. Next, we will use single-cell RNAseq (scRNAseq) to identify cell types that express SPM receptors in our mouse model of endometriosis-associated pain and confirm expression of this receptor in human lesions. When these experiments are complete, we will have identified a novel, druggable target for endometriosis therapy. As this is expected to be a GPCR, common strategies like high-throughput screening (with which we have experience) can then be used to identify pharmacophores that can serve as lead compounds for drug discovery.


Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA211646 (ZETTER, BRUCE R) Dec 23, 2016 - Nov 30, 2020
    NIH
    Assays to Identify Prostate Cancer Therapeutics Targeting Antizyme Inhibitor
    Role: Principal Investigator
  2. R01EY018829 (ROGERS, MICHAEL SEAN) May 1, 2008 - Apr 30, 2014
    NIH
    Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
    Role: Principal Investigator
  3. R21NS059411 (ROGERS, MICHAEL SEAN) Mar 5, 2007 - Feb 28, 2009
    NIH
    Assay for Inhibitors of Angiogenesis and Anthrax Toxin Receptor 1
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Ghalali A, Wang L, Stopsack KH, Rice JM, Wu S, Wu CL, Zetter BR, Rogers MS. AZIN1 RNA editing alters protein interactions, leading to nuclear translocation and worse outcomes in prostate cancer. Exp Mol Med. 2022 10; 54(10):1713-1726. PMID: 36202978; PMCID: PMC9636422.
    Citations:    Fields:    Translation:HumansCells
  2. Zaninelli TH, Fattori V, Saraiva-Santos T, Badaro-Garcia S, Staurengo-Ferrari L, Andrade KC, Artero NA, Ferraz CR, Bertozzi MM, Rasquel-Oliveira F, Manchope MF, Amaral FA, Teixeira MM, Borghi SM, Rogers MS, Casagrande R, Verri WA. RvD1 disrupts nociceptor neuron and macrophage activation and neuroimmune communication, reducing pain and inflammation in gouty arthritis in mice. Br J Pharmacol. 2022 09; 179(18):4500-4515. PMID: 35716378.
    Citations:    Fields:    
  3. Cryan LM, Tsang TM, Stiles J, Bazinet L, Lee SL, Garrard S, Madrian E, Roberts C, Payne J, Jensen A, Frankel AE, Ackroyd PC, Christensen KA, Rogers MS. Capillary morphogenesis gene 2 (CMG2) mediates growth factor-induced angiogenesis by regulating endothelial cell chemotaxis. Angiogenesis. 2022 08; 25(3):397-410. PMID: 35212873; PMCID: PMC9250616.
    Citations:    Fields:    Translation:AnimalsCells
  4. Van Egeren D, Stoddard M, Novokhodko A, Rogers MS, Joseph-McCarthy D, Zetter B, Chakravarty A. Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis. PLoS One. 2021; 16(11):e0258997. PMID: 34818335.
    Citations:    Fields:    Translation:HumansCellsPHPublic Health
  5. Van Egeren D, Novokhodko A, Stoddard M, Tran U, Zetter B, Rogers MS, Joseph-McCarthy D, Chakravarty A. Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure. Sci Rep. 2021 11 19; 11(1):22630. PMID: 34799659.
    Citations: 1     Fields:    Translation:HumansCells
  6. Fattori V, Franklin NS, Gonzalez-Cano R, Peterse D, Ghalali A, Madrian E, Verri WA, Andrews N, Woolf CJ, Rogers MS. Nonsurgical mouse model of endometriosis-associated pain that responds to clinically active drugs. Pain. 2020 06; 161(6):1321-1331. PMID: 32132396.
    Citations: 11     Fields:    Translation:HumansAnimals
  7. Finnell JG, Tsang TM, Cryan L, Garrard S, Lee SL, Ackroyd PC, Rogers MS, Christensen KA. A Canstatin-Derived Peptide Provides Insight into the Role of Capillary Morphogenesis Gene 2 in Angiogenic Regulation and Matrix Uptake. ACS Chem Biol. 2020 02 21; 15(2):587-596. PMID: 32003961.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  8. G-Doyagüez E, Carrero P, Madrona A, Rodriguez-Salamanca P, Martínez-Gualda B, Camarasa MJ, Jimeno ML, Bennallack PR, Finnell JG, Tsang TM, Christensen KA, San-Félix A, Rogers MS. Galloyl Carbohydrates with Antiangiogenic Activity Mediated by Capillary Morphogenesis Gene 2 (CMG2) Protein Binding. J Med Chem. 2019 04 25; 62(8):3958-3970. PMID: 30964669; PMCID: PMC8859974.
    Citations: 2     Fields:    Translation:AnimalsCells
  9. Ghalali A, Rice JM, Kusztos A, Jernigan FE, Zetter BR, Rogers MS. Developing a novel FRET assay, targeting the binding between Antizyme-AZIN. Sci Rep. 2019 03 15; 9(1):4632. PMID: 30874587.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  10. Dao DT, Anez-Bustillos L, Jabbouri SS, Pan A, Kishikawa H, Mitchell PD, Fell GL, Baker MA, Watnick RS, Chen H, Rogers MS, Bielenberg DR, Puder M. A paradoxical method to enhance compensatory lung growth: Utilizing a VEGF inhibitor. PLoS One. 2018; 13(12):e0208579. PMID: 30566445; PMCID: PMC6300284.
    Citations: 1     Fields:    Translation:AnimalsCells
  11. Dao DT, Anez-Bustillos L, Ourieff J, Pan A, Mitchell PD, Kishikawa H, Fell GL, Baker MA, Watnick RS, Chen H, Hamilton TE, Rogers MS, Bielenberg DR, Puder M. Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy. Angiogenesis. 2018 11; 21(4):837-848. PMID: 29956017; PMCID: PMC6463887.
    Citations: 2     Fields:    Translation:HumansAnimals
  12. Khajavi M, Zhou Y, Birsner AE, Bazinet L, Rosa Di Sant A, Schiffer AJ, Rogers MS, Krishnaji ST, Hu B, Nguyen V, Zon L, D'Amato RJ. Identification of Padi2 as a novel angiogenesis-regulating gene by genome association studies in mice. PLoS Genet. 2017 Jun; 13(6):e1006848. PMID: 28617813; PMCID: PMC5491319.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  13. Rogers MS, Novak K, Zurakowski D, Cryan LM, Blois A, Lifshits E, Bø TH, Oyan AM, Bender ER, Lampa M, Kang SY, Naxerova K, Kalland KH, Straume O, Akslen LA, Watnick RS, Folkman J, Naumov GN. Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors. Mol Cancer Res. 2014 May; 12(5):754-64. PMID: 24574516.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  14. Adini I, Ghosh K, Adini A, Chi ZL, Yoshimura T, Benny O, Connor KM, Rogers MS, Bazinet L, Birsner AE, Bielenberg DR, D'Amato RJ. Melanocyte-secreted fibromodulin promotes an angiogenic microenvironment. J Clin Invest. 2014 Jan; 124(1):425-36. PMID: 24355922; PMCID: PMC3871226.
    Citations: 28     Fields:    Translation:HumansAnimalsCells
  15. D'Amato RJ, Lentzsch S, Rogers MS. Pomalidomide is strongly antiangiogenic and teratogenic in relevant animal models. Proc Natl Acad Sci U S A. 2013 Dec 10; 110(50):E4818. PMID: 24302770.
    Citations: 3     Fields:    Translation:AnimalsCells
  16. Cryan LM, Habeshian KA, Caldwell TP, Morris MT, Ackroyd PC, Christensen KA, Rogers MS. Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay. J Biomol Screen. 2013 Jul; 18(6):714-25. PMID: 23479355.
    Citations: 8     Fields:    Translation:HumansCells
  17. Cryan LM, Bazinet L, Habeshian KA, Cao S, Clardy J, Christensen KA, Rogers MS. 1,2,3,4,6-Penta-O-galloyl-ß-D-glucopyranose inhibits angiogenesis via inhibition of capillary morphogenesis gene 2. J Med Chem. 2013 Mar 14; 56(5):1940-5. PMID: 23394144; PMCID: PMC3600088.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  18. Rogers MS, Adini I, McBride AF, Birsner AE, D'Amato RJ. The albino mutation of tyrosinase alters ocular angiogenic responsiveness. Angiogenesis. 2013 Jul; 16(3):639-46. PMID: 23423728.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  19. Rogers MS, D'Amato RJ. Common polymorphisms in angiogenesis. Cold Spring Harb Perspect Med. 2012 Nov 01; 2(11). PMID: 23125197.
    Citations: 7     Fields:    Translation:HumansAnimals
  20. Cao S, Cryan L, Habeshian KA, Murillo C, Tamayo-Castillo G, Rogers MS, Clardy J. Phenolic compounds as antiangiogenic CMG2 inhibitors from Costa Rican endophytic fungi. Bioorg Med Chem Lett. 2012 Sep 15; 22(18):5885-8. PMID: 22910038.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  21. Rogers MS, Cryan LM, Habeshian KA, Bazinet L, Caldwell TP, Ackroyd PC, Christensen KA. A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. PLoS One. 2012; 7(6):e39911. PMID: 22768167.
    Citations: 12     Fields:    Translation:AnimalsCells
  22. Rogers MS, Boyartchuk V, Rohan RM, Birsner AE, Dietrich WF, D'Amato RJ. The classical pink-eyed dilution mutation affects angiogenic responsiveness. PLoS One. 2012; 7(5):e35237. PMID: 22615734.
    Citations: 5     Fields:    Translation:Animals
  23. Cryan LM, Rogers MS. Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. Front Biosci (Landmark Ed). 2011 01 01; 16(4):1574-88. PMID: 21196249; PMCID: PMC3066103.
    Citations: 25     Fields:    Translation:HumansAnimalsCells
  24. Nakai K, Rogers MS, Baba T, Funakoshi T, Birsner AE, Luyindula DS, D'Amato RJ. Genetic loci that control the size of laser-induced choroidal neovascularization. FASEB J. 2009 Jul; 23(7):2235-43. PMID: 19237505.
    Citations: 11     Fields:    Translation:AnimalsCells
  25. Rogers MS, Christensen KA, Birsner AE, Short SM, Wigelsworth DJ, Collier RJ, D'Amato RJ. Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth. Cancer Res. 2007 Oct 15; 67(20):9980-5. PMID: 17942931.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  26. Rogers MS, Birsner AE, D'Amato RJ. The mouse cornea micropocket angiogenesis assay. Nat Protoc. 2007; 2(10):2545-50. PMID: 17947997.
    Citations: 63     Fields:    Translation:Animals
  27. Folkman J, Rogers MS. Thalidomide for multiple myeloma. N Engl J Med. 2006 Jun 01; 354(22):2389-90; author reply 2389-90. PMID: 16738279.
    Citations: 2     Fields:    Translation:Humans
  28. Rogers MS, D'Amato RJ. The effect of genetic diversity on angiogenesis. Exp Cell Res. 2006 Mar 10; 312(5):561-74. PMID: 16321383.
    Citations: 20     Fields:    Translation:HumansAnimals
  29. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell. 2005 Jan; 7(1):101-11. PMID: 15652753.
    Citations: 106     Fields:    Translation:HumansAnimalsCells
  30. Rogers MS, Rohan RM, Birsner AE, D'Amato RJ. Genetic loci that control the angiogenic response to basic fibroblast growth factor. FASEB J. 2004 Jul; 18(10):1050-9. PMID: 15226265.
    Citations: 16     Fields:    Translation:Animals
  31. Rogers MS, Rohan RM, Birsner AE, D'Amato RJ. Genetic loci that control vascular endothelial growth factor-induced angiogenesis. FASEB J. 2003 Nov; 17(14):2112-4. PMID: 12958152.
    Citations: 20     Fields:    Translation:Animals
  32. Browder T, Folkman J, Hahnfeldt P, Heymach J, Hlatky L, Kieran M, Rogers MS. Antiangiogenic therapy and p53. Science. 2002 Jul 26; 297(5581):471; discussion 471. PMID: 12143876.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  33. Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, Anderson KC, D'Amato RJ. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 2002 Apr 15; 62(8):2300-5. PMID: 11956087.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  34. D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol. 2001 Dec; 28(6):597-601. PMID: 11740816.
    Citations: 9     Fields:    Translation:Humans
  35. Rogers MS, Kobayashi T, Pittelkow MR, Strehler EE. Human calmodulin-like protein is an epithelial-specific protein regulated during keratinocyte differentiation. Exp Cell Res. 2001 Jul 15; 267(2):216-24. PMID: 11426940.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  36. Rogers MS, Strehler EE. The tumor-sensitive calmodulin-like protein is a specific light chain of human unconventional myosin X. J Biol Chem. 2001 Apr 13; 276(15):12182-9. PMID: 11278607.
    Citations: 26     Fields:    Translation:HumansCells
  37. Rogers MS, Foley MA, Crotty TB, Hartmann LC, Ingle JN, Roche PC, Strehler EE. Loss of immunoreactivity for human calmodulin-like protein is an early event in breast cancer development. Neoplasia. 1999 Aug; 1(3):220-5. PMID: 10935476.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  38. Qian H, Rogers MS, Schleucher J, Edlund U, Strehler EE, Sethson I. Sequential assignment of 1H, 15N, 13C resonances and secondary structure of human calmodulin-like protein determined by NMR spectroscopy. Protein Sci. 1998 Nov; 7(11):2421-30. PMID: 9828009; PMCID: PMC2143872.
    Citations: 2     Fields:    Translation:HumansCells
  39. Garamszegi N, Garamszegi ZP, Rogers MS, DeMarco SJ, Strehler EE. Application of a chimeric green fluorescent protein to study protein-protein interactions. Biotechniques. 1997 Nov; 23(5):864-6, 868-70, 872. PMID: 9383552.
    Citations: 2     Fields:    Translation:HumansCells
  40. Borrowman A, Rogers MS, O'Neill KL. An improved washing apparatus for nucleoside phosphorylation assays. Biotechniques. 1993 Sep; 15(3):402-4, 406. PMID: 8217151.
    Citations:    Fields:    Translation:Cells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Rogers's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (222)
Explore
_
Co-Authors (20)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.